Antibody-drug conjugates are targeted cancer therapies that combine monoclonal antibodies with cytotoxic drugs to improve efficacy while minimizing toxicity. It accounts for a significant share of oncology drug development, offering better cancer therapies. The global cancer burden is projected to reach approximately 28.4 million cases by 2040. The growing focus on precision medicine, novel linker technologies, and improved payloads is driving ADC advancements. Factors, including rising cancer prevalence, increased R&D investments, and regulatory approvals, are accelerating market growth. The antibody drug conjugates pipeline analysis by the publisher highlights various innovative treatment options that are expected to play a pivotal role in the future of cancer therapy. As the ADC pipeline continues to evolve, these therapeutics are set to revolutionize cancer treatment by offering targeted, more effective options for patients.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to antibody-drug conjugates.
Breast cancer is among the diseases treated with ADCs. These therapeutics deliver cytotoxic agents directly to malignant cells by targeting overexpressed antigens, reducing collateral damage to healthy tissues. ADCs are also used in hematologic malignancies and other solid tumors. As of January 2024, 12 antibody-drug conjugates (ADCs) had been approved by the FDA, addressing 16 different indications, including various forms of breast cancer, bladder cancer, non-small-cell lung cancer, as well as classic and non-Hodgkin lymphoma, among others. By targeting specific antigens on cancer cells, ADCs offer a precise treatment approach that enhances therapeutic effectiveness while reducing side effects, making them an essential component of modern oncology care.
Recent improvements in monoclonal antibodies for antibody-drug conjugates (ADCs) include targeting new cancer markers like HER2 and Nectin-4 and using better linkers to deliver drugs more effectively. FDA-approved ADCs like Enhertu and Padcev are helping treat cancers like breast and bladder cancer. New approaches also combine ADCs with immune therapies for better results.
This product will be delivered within 3-5 business days.
Report Coverage
The Antibody Drug Conjugates Pipeline Analysis Report by the publisher gives comprehensive insights into antibody-drug conjugates therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for antibody-drug conjugates. The antibody-drug conjugates report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The antibody-drug conjugates pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with antibody-drug conjugates treatment guidelines to ensure optimal care practices.The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to antibody-drug conjugates.
Antibody Drug Conjugates Drug Pipeline Outlook
Antibody-drug conjugates (ADCs) are targeted therapies that combine monoclonal antibodies with cytotoxic drugs. They bind specifically to tumor-associated antigens, delivering potent agents directly to cancer cells while minimizing systemic toxicity. ADCs represent a breakthrough in precision medicine, offering improved efficacy and safety over traditional chemotherapy. Their evolving design drives advancements in personalized cancer care.Breast cancer is among the diseases treated with ADCs. These therapeutics deliver cytotoxic agents directly to malignant cells by targeting overexpressed antigens, reducing collateral damage to healthy tissues. ADCs are also used in hematologic malignancies and other solid tumors. As of January 2024, 12 antibody-drug conjugates (ADCs) had been approved by the FDA, addressing 16 different indications, including various forms of breast cancer, bladder cancer, non-small-cell lung cancer, as well as classic and non-Hodgkin lymphoma, among others. By targeting specific antigens on cancer cells, ADCs offer a precise treatment approach that enhances therapeutic effectiveness while reducing side effects, making them an essential component of modern oncology care.
Antibody Drug Conjugates - Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of antibody-drug conjugates drug candidates based on several segmentations, including:By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
- Monoclonal Antibodies
- Cytotoxic Payloads
- Linkers
By Route of Administration
- Oral
- Parenteral
- Others
Antibody Drug Conjugates - Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase I covers a major share of the total antibody-drug conjugates clinical trials. Phase I constitutes the highest share in the disease market pipeline at 44.98%. Meanwhile, Early Phase I, Phase II, Phase III, and Phase IV currently hold shares at 1.06%, 39.16%, 14.29%, and 0.53%, respectively, offering promising opportunities for future development.Antibody Drug Conjugates - Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the antibody-drug conjugates pipeline analysis include monoclonal antibodies, cytotoxic payloads, and linkers. The antibody-drug conjugates report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for antibody-drug conjugates.Recent improvements in monoclonal antibodies for antibody-drug conjugates (ADCs) include targeting new cancer markers like HER2 and Nectin-4 and using better linkers to deliver drugs more effectively. FDA-approved ADCs like Enhertu and Padcev are helping treat cancers like breast and bladder cancer. New approaches also combine ADCs with immune therapies for better results.
Antibody Drug Conjugates Clinical Trials - Key Players
The report for the antibody-drug conjugates pipeline analysis covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed antibody-drug conjugates therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in antibody-drug conjugates clinical trials:- AstraZeneca
- Oxford BioTherapeutics Ltd.
- Ambrx, Inc.
- Angiex, Inc.
- Hangzhou DAC Biotechnology Co., Ltd.
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- MediLink Therapeutics (Suzhou) Co., Ltd.
- Mythic Therapeutics
- Adcendo ApS
- FibroGen Inc.
- Shanghai Miracogen Inc.
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Antibody Drug Conjugates - Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for antibody-drug conjugates. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of antibody-drug conjugates drug candidates.Drug: Trastuzumab Deruxtecan
Trastuzumab Deruxtecan, sponsored by AstraZeneca, is a targeted anti-HER2 antibody-drug conjugate designed to deliver cytotoxic agents directly to cancer cells. It is a part of a Phase IV study, which is assessing its safety in Indian patients with unresectable or metastatic HER2-positive breast cancer. The study is expected to be completed by October 2026 projecting promising safety outcomes.Drug: FDA018-ADC
FDA018-ADC is a novel antibody-drug conjugate that is actively targeting the Trop2 receptor in cancer cells. It binds to overexpressed Trop2, internalizing into tumor cells, and releasing a potent cytotoxic payload to induce cell death. Developed by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., the ADC is demonstrating promising efficacy for triple-negative breast cancer treatment. It is being further evaluated in a phase III clinical trial.Drug: ARX788
ARX788 is a HER2-targeted antibody-drug conjugate being developed for HER2-positive metastatic breast cancer patients previously treated with T-DXd. It combines a monoclonal antibody with the cytotoxic payload AS269 using proprietary technology, allowing precise conjugation. The Phase II study is examining ARX788’s safety and efficacy through Q3W IV infusions, aiming to provide improved outcomes.Key Questions Answered in the Antibody Drug Conjugates - Pipeline Insight Report
- Which companies/institutions are leading the antibody-drug conjugates drug development?
- What is the efficacy and safety profile of antibody-drug conjugates pipeline drugs?
- Which company is leading the antibody-drug conjugates pipeline development activities?
- What is the current antibody-drug conjugates commercial assessment?
- What are the opportunities and challenges present in the antibody-drug conjugates drug pipeline landscape?
- What is the efficacy and safety profile of antibody-drug conjugates pipeline drugs?
- Which company is conducting major trials for antibody-drug conjugates drugs?
- Which companies/institutions are involved in antibody-drug conjugates collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in antibody-drug conjugates?
Reasons To Buy This Report
The Antibody Drug Conjugates Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for antibody-drug conjugates. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into antibody-drug conjugates collaborations, regulatory environments, and potential growth opportunities.This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Overview of Antibody Drug Conjugates
4 Patient Profile: Antibody Drug Conjugates
5 Antibody Drug Conjugates: Epidemiology Snapshot
6 Antibody Drug Conjugates: Market Dynamics
7 Antibody Drug Conjugates: Key Facts Covered
8 Antibody Drug Conjugates, Drug Pipeline Assessment
9 Drug Pipeline Comparative Analysis
10 Antibody Drug Conjugates Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
11 Antibody Drug Conjugates Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
12 Antibody Drug Conjugates Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
13 Antibody Drug Conjugates Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
14 Antibody Drug Conjugates, Key Drug Pipeline Companies
